Jasper Therapeutics stock holds the focus. Company profile stays central.

By Christina Vaughn, Background & Management desk. Reviewed on July 7, 2026 at 11:21 a.m. ET.

Jasper Therapeutics (US47191J1060) is a clinical-stage biotechnology company listed on Nasdaq under the ticker JSPR. With no verified live catalyst in the available search results, the company profile and its development pipeline remain the main reference point for investors today.

Pipeline first

Jasper Therapeutics is developing antibody-based therapies for immune-mediated diseases, with a focus on mast-cell-driven conditions. The company describes its work as centered on its lead program briquilimab, which has been the core of its clinical story.

Nasdaq context

The Nasdaq listing gives the shares a clear US-market anchor, and that matters when traders are comparing small-cap biotech names with broader risk appetite in the sector. In this setting, the market usually reacts most to clinical updates, financing terms and trial milestones.

Briquilimab program

Briquilimab is Jasper's lead asset and the product most closely associated with the company in the market. It is being studied as a potential treatment in mast-cell-related and other immune conditions, which keeps development data at the center of the investment case.

Price and venue

As of July 7, 2026, no verified live price was available in the provided search results, so the company is best framed through its Nasdaq listing and clinical-stage profile.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.